|Using Cresset to grow and link distant fragment hits with sensible chemistry |
M J Slater; T Cheeseright
We describe a further extension to our fragment growing methodology to aid fragment optimisation through linking fragments that have been shown to bind to distinct (distant or adjacent) pockets.
|A multi-resonances valveless micropump with high fluid transportation efficiency|
Ming-Che Hsieh, Min-Fan Huang, and An-Bang Wang
A multi-resonances valveless micropump equipping with inlet/outlet elastic chambers of intendedly-designed stiffness was successfully realized to solve the low efficiency problem. Besides, a theoretical model based on Hydraulic-electrical-Analogy was also proposed to precisely predict its characteristics of dynamic behavior.
|Rate and Mechanistic Investigation of Eu(OTf)2-Mediated Reduction of Graphene Oxide at Room Temperature|
Tufan Ghosh, Sandeepan Maity and Edamana Prasad
Eu(OTf)2 has been introduced as an efficient reagent for the reduction of graphene oxide. Details kinetic studies have been performed which suggests that, the method is more efficient compared to that of other commonly used reduction methods.
|Droplet-on-Demand Platform for Biochemical Screening & Drug Discovery|
L.D. van Vliet1*, F. Gielen1, A. Sinha2, B.T. Koprowski3, J.B. Edel4, X.Niu5, A.J. deMello3, F. Hollfelder1, & J. Motschman2
To demonstrate droplet on demand applications towards study of biological entities encapsulated in nanoliter droplets. Interfacing a droplet on demand platform with microfluidic chips allows for merging and dilution of droplets. This feature is applied to encapsulate yeast cells (S. cerevisiae) and multicellular organisms (C. elegans).
|Direct Targets Identification of a Bioactive Compound|
Sylvain Blanc, Paul Bradley, Marie-Edith Gourdel, Michael Cholay, Gisèle Guimèse, Mike Mckenzie, George Nasi, Jean-Christophe and Barbara Ruggiero
Identifying protein partners of a small bioactive molecule is of great
interest in many aspects of life sciences and specifically in the drug
discovery and development process cycle. It is a support to (i) decipher
the mechanism of action after for example a “High Content” screening,
(ii) study “off-target” effects, (iii) adjust therapeutic indications and
clinical regimens of a drug and (iv) consider drug repositioning.
|3D-Tissue/ Whole-blood Co-culture Models Combined with Multi-Analyte Profile (MAP) Analyses for In-vivo-like Immunopharmacology|
Stein GM, Joos T, Schmolz M
Human Organotypic Test (HOT) Systems aim at in-vivo like substance characterisation of all preparations meant to act on the human immune system.
|Phenotypic Screening Applied to the Anti-biofilm Drug Discovery: Identification of Anti-biofilm Flavonoids from a Chemical Library|
Suvi Manner1*, Malena Skogman2, Pia Vuorela2, Adyary Fallarero2
This work represents a systematic exploration of a flavonoids collection for the inhibitory activity against Staphylococcus aureus biofilms and offers an improved methodological workflow for anti-biofilm screens of chemical libraries taking into account the connections between anti-biofilm and antibacterial properties.
|EU-OPENSCREEN - The European Research Infrastructure of Open Screening Platforms for Chemical Biology|
EU-OPENSCREEN (www.eu-openscreen.eu) is the largest emerging academic chemical biology research infrastructure initiative in Europe with the aim to collaboratively develop novel research tool compounds with external scientists. As a joint effort of national networks in 16 European countries, EU-OPENSCREEN offers access to high-throughput screening platforms, chemistry services, an open-access database, a large compound collection and an open-access database.
|Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"|
Pilar Ventosa-Andrés, Nils Ohnesorge, Yolanda Fernández, Yolanda Alvarez and Breandán Kennedy
3D-NET, “Drug Discovery & Development of Novel Eye Therapeutics”, is a new European research consortium of industry and academic partners focusing efforts to enhance the discovery and development of drugs targeting ocular pathologies that lead to blindness.